title: Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.
abstract: There have been significant advances in the treatment of multiple sclerosis (MS) in recent years, but further improvement in therapy is required as not all patients have responded optimally. An approach to enhancing MS treatment is to combine drugs that impact on different aspects of the disease process. We have described that the tetracycline derivative, minocycline, attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a model of MS. Here, we have evaluated the combination of minocycline and glatiramer acetate (GA), a current therapy in MS, on the course of EAE in mice. This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination.
authors.affiliation: Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Giuliani
authors.forename: Luanne M
authors.initials: LM
authors.lastname: Metz
authors.forename: Tammy
authors.initials: T
authors.lastname: Wilson
authors.forename: Yan
authors.initials: Y
authors.lastname: Fan
authors.forename: Amit
authors.initials: A
authors.lastname: Bar-Or
authors.forename: V Wee
authors.initials: VW
authors.lastname: Yong
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D003711:Demyelinating Diseases / Q000188:drug therapy; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D000068717:Glatiramer Acetate; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D008911:Minocycline / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000139:chemically induced / Q000188:drug therapy; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D010455:Peptides / Q000627:therapeutic use*; D016622:Silver Staining / Q000379:methods; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D007166:Immunosuppressive Agents; C571327:Mog protein, mouse; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D010455:Peptides; D000068717:Glatiramer Acetate; D008911:Minocycline